Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aptevo Therapeutics (APVO) Other Operating Expenses (2017 - 2023)

Aptevo Therapeutics (APVO) has disclosed Other Operating Expenses for 3 consecutive years, with $9.6 million as the latest value for Q1 2023.

  • Quarterly Other Operating Expenses changed N/A to $9.6 million in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $9.6 million through Dec 2023, changed N/A year-over-year, with the annual reading at $9.6 million for FY2023, N/A changed from the prior year.
  • Other Operating Expenses hit $9.6 million in Q1 2023 for Aptevo Therapeutics, down from $14.3 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $14.3 million in Q1 2020 to a low of $9.6 million in Q1 2023.